Reuters logo
BRIEF-FDA warns of heart risks with Astellas' Lexiscan and Adenoscan
November 20, 2013 / 3:15 PM / 4 years ago

BRIEF-FDA warns of heart risks with Astellas' Lexiscan and Adenoscan

Nov 20 (Reuters) - US FDA: * FDA warns of rare but serious risk of heart attack and death with Astellas

Pharma’s cardiac nuclear stress test drugs Lexiscan and Adenoscan * FDA says approved changes to drug labels to reflect the serious events &

updated recommendations for use of Astellas’ Lexiscan and Adenoscan * FDA says healthcare professionals should avoid using Astellas’ Lexiscan &

Adenoscan in patients with signs of cardiovascular instability * FDA says data limitations prevents it from determining if there is a

difference in risk of heart attack or death between Lexiscan and Adenoscan * Source text () * Further company coverage

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below